Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemo-embolization for Head and Neck Cancer
NCT04595981Phase 2Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- May 2027
- Primary completion
- May 2029
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cisplatin micelle injection (HA132) in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Alabama at Birmingham. Primary endpoint: Progression Free Survival at 6 months. Planned start May 2027; status: withdrawn.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04595981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04595981.